Stocks
Starling Oncology IncTOI
NASDAQHealthcareBiotechnology$5.13
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with specific genetic mutations. Its lead candidate, ulixertinib, targets ERK pathway alterations and is being evaluated in late-stage trials for solid tumors. Investors track the company for its potential in precision oncology and its regulatory milestones.
52W Range: $2.32-$7.05
Congressional Interest in Starling Oncology Inc (TOI)
No congressional trades have been disclosed for Starling Oncology Inc (TOI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TOI?
No congressional trades found for this stock.